APPENDIX

TABLE OF CONTENTS

Page

APPENDIX A

United States Court of Appeals for the Federal Circuit

JUNO THERAPEUTICS, INC., SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH,
Plaintiffs-Appellees

v.

KITE PHARMA, INC.,
Defendant-Appellant

2020-1758

Appeal from the United States District Court for the Central District of California in No. 2:17-cv-07639-PSG-KS, Judge Philip S. Gutierrez.

Decided: August 26, 2021

MORGAN CHU, Irell & Manella LLP, Los Angeles, CA, argued for plaintiffs-appellees. Also represented by ALAN J. HEINRICH, ELIZABETH C. TUAN; GREGORY A. CASTANIAS, JENNIFER L. SWIZE, Jones Day, Washington, DC; LISA LYNN FURBY, Chicago, IL; ANDREA WEISS JEFFRIES, Los Angeles, CA; MATTHEW J. RUBENSTEIN, Minneapolis, MN.

E. JOSHUA ROSENKRANZ, Orrick, Herrington & Sutcliffe LLP, New York, NY, argued for defendant-appellant. Also represented by MELANIE L.

BOSTWICK, ROBBIE MANHAS, JEREMY PETERMAN, Washington, DC; GEOFFREY DONOVAN BIEGLER, Fish & Richardson, San Diego, CA; TED G. DANE, PETER GRATZINGER, ADAM R. LAWTON, GARTH VINCENT, JEFFREY I. WEINBERGER, Munger, Tolles & Olson LLP, Los Angeles, CA.

Before MOORE, *Chief Judge*,
PROST and O'MALLEY, *Circuit Judges*.

MOORE, *Chief Judge*.

Kite Pharma, Inc. appeals a final judgment of the United States District Court for the Central District of California that (1) claims 3, 5, 9, and 11 of U.S. Patent No. 7,446,190 are not invalid for lack of written description or enablement, (2) the '190 patent's certificate of correction is not invalid, and (3) Juno Therapeutics, Inc., and Sloan Kettering Institute for Cancer Research (collectively, Juno) were entitled to $1,200,322,551.50 in damages. *Juno Therapeutics, Inc. v. Kite Pharma, Inc.*, No. 2:17-cv-07639-PSG-KS, (C.D. Cal. April 8, 2020), ECF 728. Because we conclude that the jury verdict regarding written description is not supported by substantial evidence, we reverse.

BACKGROUND

T cells are white blood cells that contribute to the body's immune response. J.A. 32906–07. They have naturally occurring receptors on their surfaces that facilitate their attack on target cells (such as cancer cells) by recognizing and binding an antigen, i.e., a structure on a target cell's surface. J.A. 32907–08.

Chimeric antigen receptor (CAR) T-cell therapy involves isolating a patient's T cells; reprogramming

those T cells to produce a specific, targeted receptor (a CAR) on each T cell's surface; and infusing the patient with the reprogrammed cells. J.A. 32913; '190 patent at 2:31–36, 7:24–33. The reprogramming involves introducing genetic material containing a nucleotide sequence encoding for a CAR into the T cell so that the cell produces the CAR on its surface. J.A. 32913; '190 patent at 1:30–34, 2:27–36. This CAR allows the T cell to recognize the specific antigen for which it was programmed. J.A. 32913; '190 patent at 2:27–36.

The '190 patent relates to a nucleic acid polymer encoding a three-part CAR for a T cell. It claims priority to a provisional application filed May 28, 2002, a time period that one of the inventors labeled as "the birth of the CAR-T field." J.A. 32976. The first portion of the three-part CAR is called the intracellular domain of the human CD3 ζ (zeta) chain. *See, e.g.*, '190 patent at 2:14–16, 4:12–17. It is a signaling domain that, when the T cell binds to an antigen, is activated to create an initial immune response. J.A. 103. The second portion is a costimulatory region comprising a specific amino acid sequence (SEQ ID NO:6) that is part of a naturally occurring T-cell protein called CD28. '190 patent at 2:16–17, 3:44–54. When activated, the costimulatory region creates a second signal to augment or prolong the immune response by, for example, directing the T cells to multiply. J.A. 103; J.A. 32912. The CD3-zeta portion and the costimulatory region combine to make a signaling element, or backbone, of the CAR. J.A. 32906; J.A. 32912–13. This combination of the CD3-zeta and costimulatory regions allows the T cells to not only kill target cells but also to divide into more T cells. J.A. 32913–14. The third and final portion of

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.